Keywords: celgene, mds, drug, cuts, risk, death, says

Celgene MDS drug cuts risk of death by 42%

Article | 02 March 2009

Print This

Celgene says results published in The Lancet Oncology from AZA-001, a randomized Phase III study conducted in patients with higher-risk ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in